<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897871</url>
  </required_header>
  <id_info>
    <org_study_id>CCLG-PK-2006-09</org_study_id>
    <secondary_id>CDR0000560121</secondary_id>
    <secondary_id>EU-20742</secondary_id>
    <secondary_id>EUDRACT-2006-002845-36</secondary_id>
    <nct_id>NCT00897871</nct_id>
  </id_info>
  <brief_title>Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer</brief_title>
  <official_title>Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from young patients with cancer may
      help doctors learn how carboplatin, cyclophosphamide, and etoposide affect the body and how
      patients will respond to treatment.

      PURPOSE: This laboratory study is evaluating the side effects and how well anticancer drugs
      work in very young patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Investigate inter-individual variability in the pharmacokinetics of selected anticancer
           drugs in infants and children age &lt; 2 years on current dosing schedules.

        -  Compare drug exposures and degree of pharmacokinetic variability in children &lt; 2 years
           with data obtained from published studies in older children.

        -  Relate inter-individual variability in pharmacokinetics and drug exposure to clinical
           toxicity and response.

        -  Use pharmacokinetic data in conjunction with clinical information obtained following
           treatment to investigate the suitability of current dosing regimens in infants and young
           children.

      OUTLINE: This is a multicenter study. Patients are stratified according to age in months (0
      to 6 vs 6 to 12 vs 12 to 24).

      Patients receive carboplatin, cyclophosphamide, or etoposide according to the dosing regimen
      detailed in the clinical protocol on which the child is being treated.

      Blood samples are collected from patients receiving 1 of the 3 drugs by central venous
      catheter periodically during treatment to measure pharmacokinetics of the specific drug.
      Additional blood samples are collected for DNA extraction and polymorphism analysis in
      CYP2B6, CYP2C9, and other metabolizing enzymes in addition to the determination of the
      genetic variation in multiple drug resistance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic modelling comparing pharmacokinetic parameters to investigate the key factors involved in determining individual exposures to parent drugs and metabolites</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on event-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of childhood cancer

          -  Receiving carboplatin, cyclophosphamide, or etoposide as standard treatment as part of
             a clinical study at a Children's Cancer and Leukemia Group (CCLG) center

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Single or double lumen central venous catheter in place

          -  No concurrent anticonvulsants, azole antifungal agents, or chronic steroid treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gareth Veal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Newcastle Upon-Tyne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>353-1-409-6659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin W. English, MD</last_name>
      <phone>44-121-333-8412</phone>
      <email>martin.english@bch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-342-0205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amos Burke, MD</last_name>
      <phone>44-1223-348-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Glaser, MD</last_name>
      <phone>44-113-206-4984</phone>
      <email>adam.glaser@leedsth.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johann Visser, MD</last_name>
      <phone>44-116-258-5309</phone>
      <email>johannes.visser@uhl-tr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather P. McDowell, MD</last_name>
      <phone>44-151-293-3679</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PCE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Michelagnoli, MD</last_name>
      <phone>44-20-7380-9064</phone>
      <email>maria.michelagnoli@uclh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gill Levitt, MD</last_name>
      <phone>44-20-7405-9200 ext. 0073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Brennan, MD</last_name>
      <phone>44-161-922-2227</phone>
      <email>bernadette.brennan@cmmc.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir James Spence Institute of Child Health at Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliet Hale, MD</last_name>
      <phone>44-191-282-4101</phone>
      <email>j.p.hale@ncl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hewitt, MD, BSc, FRCP, FRCPCH</last_name>
      <phone>44-115-924-9924 ext. 63394</phone>
      <email>martin.hewitt@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Wheeler, MD</last_name>
      <phone>44-186-522-1066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary P. Gerrard, MBChB, FRCP, FRCPCH</last_name>
      <phone>44-114-271-7366</phone>
      <email>mary.gerrard@sch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice A. Kohler, MD, FRCP</last_name>
      <phone>44-23-8079-6942</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Taj, MD</last_name>
      <phone>44-20-8642-6011 ext. 3089</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony McCarthy, MD</last_name>
      <phone>44-289-063-3631</phone>
      <email>anthonymcarthy@royalhospital.n.i.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Neefjes</last_name>
      <phone>44-1224-550-217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH9 1LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Hamish Wallace, MD</last_name>
      <phone>44-131-536-0426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milind D. Ronghe, MD</last_name>
      <phone>44-141-201-9309</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital for Wales</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Traunecker, MD, PhD</last_name>
      <phone>44-29-2074-2285</phone>
      <email>heidi.traunecker@cardiffandvale.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

